SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event) July 25, 2012; (July 20, 2012)
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
| | | |
| Delaware | 0-22179 | 58-2029543 |
| (State or Other Jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
| Incorporation) | | |
| | |
5835 Peachtree Corners East, Suite D Norcross, Georgia (Address of Principal Executive Offices) | 30092 (Zip Code) |
Registrant's Telephone Number, Including Area Code: (770) 242-8723
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| | [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| | [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | |
| | [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | | |
Section 7.01 (Regulation FD Disclosure)
On July 25, 2012, the registrant publicly issued a press release announcing it had reached an agreement with the U.S. Food and Drug Administrationon a plan going forward for the Company’s LuViva® Advanced Cervical Scan premarket approval application currently under review by the agency, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| | |
| Number | Exhibit |
| 99.1 | Press Release dated July 25, 2012 |
| | |
| | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | GUIDED THERAPEUTICS, INC. | |
| | | | |
| | By: | /s/ Mark L. Faupel, Ph.D. | |
| | | Mark L. Faupel, Ph.D. | |
| | | CEO & President | |
| Date: July 25, 2012 | | | |
